IP Library › Granted Patent US 11,746,120
Granted Patent B2
US 11,746,120 · App. 18/045,390 · Granted Sep 5, 2023

Stat degraders and uses thereof

Inventors: Nello Mainolfi (Belmont, MA); Nan Ji (Arlington, MA); Bin Yang (Lexington, MA); Yi Zhang (Belmont, MA)
Assignee: Kymera Therapeutics, Inc.
C07F9/6561C07F9/65068A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,746,120
App. No.
18/045,390
Granted
Sep 5, 2023
Kind
B2
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Claims (60)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

25. The compound of claim 1 , wherein said compound is

or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

27. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

28. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

29. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

30. The pharmaceutical composition of claim 26 , wherein said compound is selected from the group consisting of

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2023
From: MAINOLFI, NELLO; JI, NAN; YANG, BIN; ZHANG, YI
To: KYMERA THERAPEUTICS, INC.
Reel/Frame 062683/0992 →
Continuity (16)
Continuation 17736669 · May 4, 2022
Division 16841095 · Apr 6, 2020
Provisional Application 62967921 · Jan 30, 2020
Provisional Application 62949053 · Dec 17, 2019
Provisional Application 62947310 · Dec 12, 2019
Provisional Application 62944810 · Dec 6, 2019
Provisional Application 62932957 · Nov 8, 2019
Provisional Application 62926127 · Oct 25, 2019
Provisional Application 62887872 · Aug 16, 2019
Provisional Application 62877051 · Jul 22, 2019
Provisional Application 62875362 · Jul 17, 2019
Provisional Application 62860512 · Jun 12, 2019
Provisional Application 62855259 · May 31, 2019
Provisional Application 62833331 · Apr 12, 2019
Provisional Application 62830095 · Apr 5, 2019
Related Publication 20230120381A1 · Apr 20, 2023
Cited By (7)
US 12,258,341 US 12,404,509 US 12,539,295 US 12,545,659 US 12,551,564 US 12,558,427 US 12,570,679